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Abstract
Background: Ki-1 (CD30) antigen expression is not found on peripheral blood cells but its expression can be
induced in vitro on T and B lymphocytes by viruses and lectins. Expression of CD30 in normal tissues is very
limited, being restricted mainly to a subpopulation of large lymphoid cells; in particular, cells of the recently
described anaplastic large cell lymphoma (ALCL), the Reed-Sternberg (RS) cells of Hodgkin's lymphoma and
scattered large parafollicular cells in normal lymphoid tissues. More recent reports have described CD30
expression in non-hematopoietic and malignant cells such as cultured human macrophages, human decidual cells,
histiocytic neoplastic cells, mesothelioma cells, embryonal carcinoma and seminoma cells.
Results: We investigated the immunohistochemical expression of CD30 antigen in 15 paraffin-embedded tissue
samples representing small intestines from fetuses after spontaneous abortion in the 8th, 10th and 12th weeks
using the monoclonal antibody Ki-1. Hormones had been administered to all our pregnant women to support
gestation. In addition, a panel of monoclonal antibodies was used to identify leukocytes (CD45/LCA), B-
lymphocytes (CD20/L-26) and T-lymphocytes (CD3). Our findings were correlated with those obtained
simultaneously from intestinal tissue samples obtained from 15 fetuses after therapeutic or voluntary abortions.
Conclusions: The results showed that: (1) epithelial cells in the developing intestinal crypts express the CD30
(Ki-1) antigen; (2) CD30 expression in these epithelial cells is higher in cases of hormonal administration than in
normal gestation. In the former cases (hormonal support of gestation) a mild mononuclear intraepithelial infiltrate
composed of CD3 (T-marker)-positive cells accompanies the CD30-positive cells.
Published: 11 January 2005
Theoretical Biology and Medical Modelling 2005, 2:1 doi:10.1186/1742-4682-2-1
Received: 20 September 2004
Accepted: 11 January 2005
This article is available from: http://www.tbiomed.com/content/2/1/1
© 2005 Tamiolakis et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Theoretical Biology and Medical Modelling 2005, 2:1 http://www.tbiomed.com/content/2/1/1
Page 2 of 6
(page number not for citation purposes)
Introduction
CD30 antigen, a member of the tumor necrosis factor
(TNF) receptor superfamily [1-3], was originally identi-
fied as a cell surface antigen on primary and cultured
Hodgkin's and Reed-Sternberg cells by use of the mono-
clonal antibody Ki-1 [4,5]. CD30 antigen is normally
expressed by a subset (15–20%) of CD3+ T cells after acti-
vation by various stimuli [6]. Its expression is stimulated
by interleukin (IL)-4 during lineage commitment of naïve
human T cells [7,8] and is augmented by the presence of
CD28 co-stimulatory signals [9]. CD30 also is expressed
at variable levels in different non-Hodgkin's lymphomas
(NHL) as well as in several virally transformed T and B cell
lines [5,10]. In particular, CD30 is a specific marker of a
subset of peripheral T cell NHLs known as anaplastic large
cell lymphomas (ALCL) [5]. More recently, preferential
CD30 expression has been detected on a subset of tissue
and circulating CD4+ and CD8+ T cells producing mainly
Th2 cytokines in immunoreactive conditions [11-14].
CD30 appears to have an important immunoregulatory
role in normal T cell development. Within the thymus,
CD30L is highly expressed on medullary thymic epithelial
cells and on Hassal's corpuscles [15].
Pallesen and Hamilton-Dutoir [16] were the first to report
CD30 expression outside lymphoid tissue in 12 out of 14
cases of primary or metastatic embryonal carcinoma (EC)
of the testis, using immunostaining with the monoclonal
antibodies (MAbs) Ber-H2 and Ki-1. Subsequently, sev-
eral investigators have confirmed their results and have
detected CD30 in these carcinomas at the protein [17-20]
and the mRNA [10] level. Two reports demonstrated
CD30 expression in 4/21 and 4/63 cases of testicular and
mediastinal seminoma [21] and in the seminomatous
components of 7/14 cases of mixed germ cell tumours of
the testis [22]. Suster et al. detected the CD30 antigen in
6/25 yolk sac tumours of the testis and mediastinum [22].
CD30 expression has also been reported in other non-
lymphoid tissues and cells such as soft tissue tumours
[23], decidual cells [24,25], lipoblasts [26], myoepithelial
cells [27], reactive and neoplastic vascular lesions [28],
mesotheliomas [29], cultivated macrophages, and two
histiocytic malignancies [30].
Primitive crypts (epithelial downgrowths into the mesen-
chyme between the small intestinal villi), appear in the
postpharyngeal foregut between the 9th and 12th weeks of
embryo development. Goblet cells are present in small
numbers after 8 weeks, Paneth cells differentiate at the
base of the crypts in weeks 11 and 12, and enteroendo-
crine cells appear between weeks 9 and 11.
The fact that the CD30 molecule can mediate signals for
cell proliferation or apoptosis [2] prompted us to perform
a systematic investigation of CD30 antigen expression in
non-hematopoietic embryonal tissues during the prolifer-
ation and differentiation stages, beginning with the epi-
thelial cells of the developing intestinal crypts.
Materials and methods
Samples representing 15 small intestines from fetuses
after spontaneous (involuntary) abortion occurring in
pregnant women treated with progesterone (300–600 mg
per day until the 12th gestational week), and 15 small
intestines from fetuses after therapeutic or voluntary abor-
tion, were obtained in the 8th, 10th and 12th weeks of
gestation. The Regional Ethics Committees approved the
study. Written informed consent was obtained from all
individuals and the procedures followed accorded with
institutional guidelines. Small intestines were cut in 3 mm
slices and fixed in 10% neutral buffered formaldehyde at
4°C for 24 h, then processed for routine paraffin embed-
ding. Paraffin blocks were available in all cases, and 3 µm
thick tissue sections were stained routinely with hematox-
ylin-eosin, PAS and Giemsa, and subsequently by immu-
nohistochemistry. Immunoperoxidase labeling was
performed as follows: sections were deparaffinized in
70% alcohol and endogenous peroxidase was blocked
with 3% H2O2 in methanol. The sections were preincu-
bated in 20% serum of the species from which the second-
ary antibody was raised, and the primary antibody was
applied. After overnight incubation at room temperature,
the secondary biotinylated antibody was applied for 30
min. Staining was visualized with a Vector Elite System
(Vector Laboratories, Burlingame, CA) using diaminoben-
zidine as the chromogen. The sections were counter-
stained with dilute hematoxylin. The primary antibodies
used were as follows: (CD30/Ki-1) activated lymphoid
cells, mouse monoclonal antibody (Novocastra); (CD45/
LCA) leukocyte common antigen, mouse monoclonal
antibody (Dako); (CD20/L-26) B-lymphocytes, mouse
monoclonal antibody (Dako); and (CD3) T-lymphocytes,
mouse monoclonal antibody (Dako). We used the high
temperature antigen unmasking technique for immuno-
histochemical demonstration of CD30/Ki-1 on paraffin
sections (Novocastra). Control slides were incubated with
nonimmunized rabbit serum. An anaplastic lymphoma
case-slide (positive control) was run in parallel with the
assay.
Analysis of CD30/Ki-1 positive cryptae cells
For each sample, the CD30/Ki-1 positive population was
assessed by enumeration of labeled cells in each tissue
compartment for a minimum of five random fields per
section viewed at 40-fold magnification through a grid.
Cell numbers were calculated per mm2 of tissue section.
The counted areas were selected from random tissue sec-
tions, taking into account that the ratio of the area of the
intestinal stroma to the area of surface epitheliumTheoretical Biology and Medical Modelling 2005, 2:1 http://www.tbiomed.com/content/2/1/1
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covering the crypts was representative of the entire field.
Areas with obvious necrosis or haemorrhages were
excluded. Statistical analysis was performed using the
ANOVA test.
Results
Five microscopic fields of the small intestines were evalu-
ated in each case without knowledge of the clinical data
(TABLE 1). Two observers examined the sections inde-
pendently, and positive cellular staining for each antibody
was manifested as fine brown cytoplasmic granularity
and/or surface membrane expression.
8th week of gestation
In cases of spontaneous (involuntary) abortion, immuno-
histochemistry revealed small clusters or scattered, large-
sized CD30/Ki-1 positive cryptae cells within the intestine
in all settings examined (Fig. 1), with percentages varying
from 3.2 to 3.9 (mean ± sd = 3.61 ± 0.16). In the neigh-
bouring intestinal stroma a slight cellular infiltration was
observed, consisting of rounded mononuclear cells
approximately 10 µm in diameter with eccentric kidney-
shaped nuclei and expressing a CD45/LCA and CD3 phe-
notype. In cases of voluntary or therapeutic abortion,
immunohistochemistry showed a smaller number of
large-sized CD30/Ki-1 positive cryptae cells in all settings
examined (Fig. 2), with percentages varying from 3.1 to
3.7 (mean ± sd = 3.42 ± 0.17). No inflammatory infiltrates
or necrosis were noted in the neighbouring intestinal
stroma.
10th week of gestation
In cases of spontaneous abortion, immunohistochemistry
showed a higher number of positive CD30/Ki-1 cryptae
cells than at the 8th week of gestation (Fig. 3), with per-
centages varying from 4.9 to 5.6 (mean ± sd = 5.27 ±
0.19). There were very few inflammatory infiltrates in the
intestinal stroma expressing the phenotype CD45/LCA
and CD3. In cases of voluntary or therapeutic abortion,
the frequency of CD30/Ki-1 positive cryptae cells was sim-
ilar to that at the 8th week of gestation, with percentages
varying from 3.2 to 3.9 (mean ± sd = 3.43 ± 0.18). No
inflammatory infiltrates or necrosis were noted in the
neighbouring intestinal stroma.
Table 1: Expresion of CD30 antigen in fetal intestinal cryptae cells during the first trimester of gestation.
Spontaneous abortions Voluntary abortions
8th week 10th week statistics 8th week 10th week statistics
CD30(+)cells/mm2 3.61+/0.16 5.27+/-0.19 p < 0.0001 3.42+/-0.17 3.43+/-0.18 p = 0.95
8th week 12th week statistics 8th week 12th week statistics
CD30(+)cells/mm2 3.61+/-0.16 5.34+/-0.23 p < 0.0001 3.42+/-0.17 3.41+/-0.17 p = 0.95
8th week of gestation (involuntary abortions) Figure 1
8th week of gestation (involuntary abortions). Ki-1 
(CD30) antigen is expressed by a small number of epithelial 
cryptae cells. Immunohistochemical stain X 400.
8th week of gestation (voluntary abortions) Figure 2
8th week of gestation (voluntary abortions). Weak to 
moderate expression of Ki-1 (CD30) antigen in the develop-
ing crypts. Immunohistochemical stain X 400.Theoretical Biology and Medical Modelling 2005, 2:1 http://www.tbiomed.com/content/2/1/1
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12th week of gestation
In spontaneous abortion cases the number of CD30/Ki-1
positive cryptae cells was even higher than at 10th week,
with percentages varying from 4.8 to 5.7 (mean ± sd =
5.34 ± 0.23). The number in cases of voluntary or thera-
peutic abortions was more or less the same as at 8th and
10th weeks, with percentages varying from 3.2 to 3.7
(mean ± sd = 3.41 ± 0.17). No differences in immune
reaction were noted in the neighbouring intestinal stroma
in cases of either spontaneous or voluntary/therapeutic
abortion in comparison to the 8th and 10th gestational
weeks.
The differences among the numbers of CD30/Ki-1 posi-
tive cells at the 8th, 10th and 12th gestational week after
spontaneous abortion were statistically significant (p <
0.0001). No significant differences were observed in the
numbers of these cells after voluntary or therapeutic abor-
tions (p = 0.95).
Discussion
The value of the CD30 antigen as a diagnostic marker for
Hodgkin's lymphoma and anaplastic large cell lymphoma
is well documented [4,5,31]. However, the function of
this cytokine receptor in Hodgkin's lymphoma and other
CD30-positive diseases is still not clear.
CD30 appears to have an important immunoregulatory
role in normal T cell development. In normal cells, this
transmembrane glycoprotein can be induced on B and T
lymphocytes by mitogen stimulation or viral transforma-
tion [32-34]. cDNA cloning has revealed that the CD30
protein is a cytokine receptor of the tumor necrosis factor
receptor superfamily [1,35], the ligand of which belongs
to the tumor necrosis factor family [22,23].
Recent in vitro data indicate that the CD30 receptor-lig-
and complex can mediate signals for cell proliferation,
apoptosis and cytotoxicity in lymphoid cells [20,36,37].
Our results give the first indication that the CD30 antigen
is expressed in the epithelial cells of developing intestinal
crypts. This observation has a number of important impli-
cations. First, our findings are of significance with regard
to the accepted origin of R-S cells. Care must be taken
when drawing histogenetic conclusions based on the
identification of a single marker in different cell types.
Shared expression of CD30 antigen does not necessarily
relate Hodgkin and R-S cells to activated lymphocytes.
The identification of this antigen in cells as apparently dis-
parate as activated lymphocytes, R-S cells and now human
epithelial cells of the developing fetal intestinal crypts
suggests that previous views about the nature of the Ki-1
antigen must be re-examined. The Hodgkin and Reed-
Sternberg cells are indeed lymphocytes as they harbor
rearranged immunoglobulin (in more than 90% of cases)
and T cell receptors [38]. Although the expression of
CD30 antigen may indicate a relationship between these
cell types, it is likely to be less straightforward than was
previously supposed. Identification of the normal
physiological role of CD30 antigen is thus made even
more imperative if these relationships are to be
understood.
Second, these findings indicate that outside the lymphatic
system, CD30 antigen expression in the epithelial cells of
developing intestinal crypts can mediate signals for cell
proliferation and differentiation in a region where other
cell types (stem, goblet, Paneth and enteroendocrine)
grow throughout life.
Third, CD30 expression in the epithelial cells of the devel-
oping intestinal crypts is induced by progesterone. This is
a novel mechanism of CD30 induction, distinct from neo-
plastic transformation and viral infection of lymphocytes.
The demonstration of large R-S like cells in the developing
crypts within a lymphoplasmacytic infiltrate, in the same
way that similar R-S like cells are observed in reactive
lymph nodes, especially within the parafollicular areas, is
evidence that such cells might represent the physiological
counterparts of R-S cells.
The possibility that CD30 is an oncofetal antigen is sup-
ported by our positive findings in fetal intestinal cryptae
cells. We have so far been able to investigate only a single
tissue from a small number of fetuses of early gestational
age. Pallesen and Hamilton-Dutoit [16] examined CD30
expression in normal adult, neonatal and fetal (week 28)
testes, as well as other tissues (brain, spinal cord, lung,
10th week of gestation (involuntary abortions) Figure 3
10th week of gestation (involuntary abortions). Strong 
expression of Ki-1 (CD30) antigen in the developing crypts. 
Immunohistochemical stain X 400Theoretical Biology and Medical Modelling 2005, 2:1 http://www.tbiomed.com/content/2/1/1
Page 5 of 6
(page number not for citation purposes)
gut, kidney, erythropoietic tissue, muscle, bone and con-
nective tissue) from fetuses of 11 and 12 weeks gestational
age, with negative results. This is the first demonstration
of CD30 in epithelial cells in fetal tissue. Although our
results require confirmation from frozen sections, they –
together with a reported positive staining in placenta
[24,25] – suggest that the antigen is expressed by prolifer-
ating and differentiating epithelial cells of other than lym-
phoid origin. Clearly the extent of expression of CD30
antigen in embryonal tissues warrants further
investigation.
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